Solid gastrointestinal tumours have been reported to express sex steroid receptors (e.g. oestrogen (McCleadon et al., 1977; Leake et al., 1980; Niski et al., 1987), progesterone (Sica et al., 1984) ) or specific receptors for gastrointestinal hormones (e.g. gastrin (Rae-Venter et al., 1981) ), somatostatin (Viguerie et al., 1980) and vasoactive intestinal peptide (Estival et al., 1983) . The monoclonal antibody D5 detects the 29 kD phosphoprotein, p29. D5 was first raised against partially purified human uterine oestrogen receptor (Coffer et al., 1977) . In primary breast tumours D5 staining correlated significantly with oestrogen receptor status but not progesterone receptor status (Cano et al., 1986) . D5 staining of the primary tumour, like oestrogen receptor status, correlated well with response to endocrine therapy (Cano et al., 1986) . This correlation in patients with breast cancer between D5 immunostaining and response to endocrine therapy has been confirmed (Heyderman et al., 1989) . However, it has been shown that while oestrogen receptor is localised mainly to the nucleus in breast cancer, D5 staining is mainly cytoplasmic (King et al., 1985) .
The prognostic value of the monoclonal antibody (D5) detected protein, p29, in primary colorectal carcinoma (McCleadon et al., 1977; Leake et al., 1980; Niski et al., 1987) , progesterone (Sica et al., 1984) ) or specific receptors for gastrointestinal hormones (e.g. gastrin (Rae-Venter et al., 1981) ), somatostatin (Viguerie et al., 1980) and vasoactive intestinal peptide (Estival et al., 1983) . The monoclonal antibody D5 detects the 29 kD phosphoprotein, p29. D5 was first raised against partially purified human uterine oestrogen receptor (Coffer et al., 1977) . In primary breast tumours D5 staining correlated significantly with oestrogen receptor status but not progesterone receptor status (Cano et al., 1986) . D5 staining of the primary tumour, like oestrogen receptor status, correlated well with response to endocrine therapy (Cano et al., 1986) . This correlation in patients with breast cancer between D5 immunostaining and response to endocrine therapy has been confirmed (Heyderman et al., 1989) . However, it has been shown that while oestrogen receptor is localised mainly to the nucleus in breast cancer, D5 staining is mainly cytoplasmic (King et al., 1985) .
Our own group has previously reported on the influence of D5 immunoreactivity and the effect of the anti-oestrogen tamoxifen on survival in patients with gastric carcinoma (Harrison et al., 1989 None of the 68 patients were treated post-operatively with systemic therapy. All patients were followed up regularly in the out-patient clinic.
Of the 54 patients who initially presented with locoregional disease and had excision of the primary tumour, time to recurrence was known for 52 of these patients and these 52 patients have been used in calculating the probability of recurrence after potentially curative surgery. Survival data is available on 67 of the 68 patients.
The significance of differences between groups in either recurrence or survival were tested using the Mantel-Cox/ generalised Savage test. D5 immunoreactivity was measured on all 68 primary colorectal tumours as previously described (Harrison et al., 1989 (Dixon, 1985) . Two analogues of nonparametric rank tests, the Mantel-Cox (Mantel, 1966) and the Breslow test (Breslow, 1970) were used to determine whether the survival curves obtained for the defined groups were significantly different.
Twenty-nine patients had D5 negative tumours. Of the 39 patients who had D5 positive tumours 12 had slight focal positivity, 26 had moderate focal positivity while the remaining patient had diffuse immunopositivity. There was no correlation between D5 status and the patients sex (Table I ).
There was also no correlation between D5 status and tumour site, tumour stage, histological grade of malignancy or tumour ploidy (Table I) . D5 status (negative vs positive) was correlated with the probability of recurrence (Mantel-Cox statistic 0.238, 1 d.f.; P = 0.63) (Figure 1 ). Patients with D5 positive tumours were further subdivided into slightly focal, moderately focal and diffusely positive staining: there was no correlation between the degree of immunoreactivity and recurrence (Mantel-Cox statistic = 1.11, 3 d.f.; P = 0.78). Although there was no difference in D5 status by patients' sex the probability of recurrence by D5 status was analysed separately for male (Mantel-Cox statistic = 0.2, 1 d.f.; P = 0.6) and female patients (Mantel-Cox statistic = 0.1, 1 d.f.; P = 0.7); there was no correlation. D5 status showed no correlation with overall survival (Figure 2 ). There was also no correlation between the degree of D5 immunoreactivity and survival (Mantel-Cox statistic = 0.96, 3 d.f.; P =0.81). At 30 months this study had a 80% power of showing a 25% difference in survival between the two groups at the 5% level.
The D5 antibody used in this study identifies an oestrogen receptor related protein rather than the oestrogen receptor itself. We chose this antibody because we had shown that D5 immunoreactivity was an independently significant prognostic factor in another solid gastrointestinal tumour.
In gastric cancer we have previously shown that 56% of primary tumours show positive D5 immunoreactivity (Harrison et al., 1989) . In this study of colorectal cancer 57% of primary tumours showed positive staining for D5. As in gastric cancer there was no correlation between D5 immunoreactivity and patient sex, tumour stage or histological grade of malignancy. In addition this study found no correlation 100 t--' Test statistics go '0.003 p = 0.9534 (Breslow) 0.005 p = 0.9420 (Mantel-Cox) . Figure 2 Survival vs D5 status. -*-D5 Pos; -+-D5 neg.
between D5 immunoreactivity and tumour DNA ploidy. However D5 status of colorectal tumours did not correlate with recurrence free survival or overall survival. One explanation may be that the study had only an 80% change of showing a large (i.e. 25%) difference in survival. In gastric cancer most patients present with advanced disease. Deaths are frequent in such patients and the large number of events give power to the survival analysis. Since most patients with gastric cancer have advanced disease at presentation the intrinsic biology of the tumour is important in patients' survival. This may therefore explain why the intrinsic tumour biological factor D5 is expressed in a similar percentage of gastric and colorectal primary tumours, but has been shown to be of prognostic significance only in gastric cancer. Of the 68 patients with colorectal cancer in this study more than 50% are still alive after a median follow-up of 40 months.
The relationship between D5 immunoreactivity and oestrogen receptor (ER) expression has not been established in colorectal cancer. While the lack of prognostic value of D5 in colorectal cancer is disappointing, its significance with respect to the sensitivity of colorectal cancer to sex steroid hormones is uncertain.
